729
Participants
Start Date
July 31, 2008
Primary Completion Date
April 30, 2009
Study Completion Date
July 31, 2009
Zonisamide SR placebo/ bupropion SR placebo
2 placebo combination tablets twice daily for 16 weeks (maintenance period)
Zonisamide SR placebo/ bupropion SR 360 mg/day
2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 120 mg/day/ bupropion SR placebo
2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 360 mg/day/ bupropion SR placebo
2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
Behavioral Medical Research, Staten Island
Washington Center for Weight Management and Research, Arlington
Wake Research Associates, LLC, Raleigh
Internal Medicine Associates of Charlotte, Charlotte
CSRA Partners in Health, Inc., Augusta
Miami Research Associates, Miami
SelfCenter, PC, Fairhope
Welborn Clinic, Evansville
Summit Research Network (Michigan), Inc., Farmington Hills
Radiant Research, Chicago, Chicago
Mercy Health Research, St Louis
Pennington Biomedical Research Center, Baton Rouge
The Cooper Institute, Dallas
Center for Human Nutrition/UCD, Denver
Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine, Reno
Nutrition and Metabolic Research, La Jolla
Summit Research Network (Oregon), Inc., Portland
Summit Research Network (Seattle), LLC., Seattle
Nutrition and Weight Management Center, Boston Medical Center, Boston
FutureCare Studies, Springfield
Lead Sponsor
Orexigen Therapeutics, Inc
INDUSTRY